✨ Your Portfolio is fetched and updated from zerodha.
Market Cap
₹28,554 Cr.
P/E
48.63
About
Established in 1976, J.B. Chemicals & Pharmaceuticals Limited is a rapidly growing Indian pharmaceutical company. It focuses on manufacturing and marketing pharmaceutical formulations, herbal remedies… Read more
Established in 1976, J.B. Chemicals & Pharmaceuticals Limited is a rapidly growing Indian phar… Read more
Low
1244
52W Range
High
2030
Quick View
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max

Company Timeline

Custom financial statement
Edit rows
Forensics

11 Yes

Positive for this company

2 Neutral

Neutral for this company

4 No

Negative for this company

0 No Data

Insufficient data to analyse

Market Share
0.04 %
(as of Jul 22)
Anti - Diabetes - Market Share
0.02 %
(as of Jul 22)
Anti-Infectives - Market Share
0.16 %
(as of Nov 21)
Blood Related - Market Share
2 %
(as of Jul 22)
Cardiovascular - Market Share
0.21 %
(as of Nov 21)
Dermatology - Market Share
0.07 %
(as of Nov 21)
Endocrinology - Market Share
Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Customer Wise Break-Up

Asset Break-Up - Segment Wise

Operational Metrics

    Select a Metric
    • Number of ANDA's Filed in USA (.)
    • Number of ANDA's Approved By USFDA (.)
    • Domestic Sales Growth - YoY (%)
    • R&D as a % of Total Sales (%)
    Peer Comparison
    FAQs on JB Chemicals & Pharmaceuticals Ltd. Business

    J.B. Chemicals & Pharmaceuticals Limited, established in 1976, is a fast-growing Indian pharmaceutical company specializing in manufacturing pharmaceutical formulations, herbal remedies, and APIs for innovative specialty products.

    JB Chem & Pharma major competitors are Gland Pharma, Natco Pharma, Pfizer, Alembic Pharma, Ipca Laboratories, Eris Lifesciences, Jubilant Pharmova.
    Market Cap of JB Chem & Pharma is ₹29,485 Crs.
    While the median market cap of its peers are ₹25,190 Crs.

    JB Chem & Pharma seems to be financially stable compared to its competitors.
    The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

    Company Filing
    2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release Mar Jun Sep Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Investor Presentation Mar Jun Sep Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Conference Call Mar Jun Sep Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Conference Call SummaryCon Call Summary Jun Sep Mar Jun Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Discussions & Analysis